Amicus Therapeutics Goodwill

Amicus Therapeutics posts a goodwill of $200M as of December 2025. That compares with $200M in the prior-year period — up 0.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Amicus Therapeutics's goodwill was $200M. The latest reading is $200M — essentially flat versus a year earlier (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of Amicus Therapeutics's financial statement story. At $200M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for FOLD's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Amicus Therapeutics's other metric pages and overview cover the third.

Judging Amicus Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in goodwill easier to interpret. Start with $200M here, then scan peer and history charts to see if the gap is persistent.